Effect of bicalutamide 150 mg on PSA progression in MO prostate cancer: Results from the Early Prostate Cancer program.

被引：0
|
作者：
See, W. A.
McLeod, D. G.
Iversen, P.
Wirth, M. P.
Armstrong, J.
Navani, S.
机构：
[1] Med Coll Wisconsin, Milwaukee, WI 53226 USA
[2] Walter Reed Army Med Ctr, Washington, DC 20307 USA
[3] Rigshosp, DK-2100 Copenhagen, Denmark
[4] Tech Univ Dresden, D-8027 Dresden, Germany
[5] AstraZeneca, Macclesfield, Cheshire, England
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2006年 / 24卷 / 18期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：247S / 247S
页数：1
相关论文
共 50 条
  • [41] Adjuvant bicalutamide therapy improves prognosis in early prostate cancer
    不详
    RADIOLOGE, 2006, 46 (02): : 167 - 168
  • [42] Results of a screening program in Germany for early detection of early prostate cancer
    Altwein, JE
    Luboldt, HA
    PROSTATE CANCER AND PROSTATIC DISEASES, 1999, 2 (Suppl 2) : S15 - S18
  • [43] Tamoxifen as prophylaxis for prevention of gynaecomastia and breast pain associated with bicalutamide 150 mg monotherapy in patients with prostate cancer
    Fradet, Y.
    Egerdie, B.
    Andersen, M.
    Tammela, T. L. J.
    Nachabe, M.
    Armstrong, J.
    Morris, T.
    Navani, S.
    EUROPEAN UROLOGY SUPPLEMENTS, 2007, 6 (02) : 28 - 28
  • [44] Results of a screening program in Germany for early detection of early prostate cancer
    JE Altwein
    HA Luboldt
    Prostate Cancer and Prostatic Diseases, 1999, 2 : S15 - S18
  • [45] The influence of nodal status on progression outcomes in patients with prostate cancer: Data from the Early Prostate Cancer program at 7.4 years.
    Iversen, P.
    Wirth, M. P.
    See, W. A., II
    Mcleod, D. G.
    Morris, T.
    Armstrong, J.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 248S - 248S
  • [46] Comparative Study Evaluating Safety and Efficacy of Bicalutamide (150 mg) Monotherapy versus Orchidectomy and Bicalutamide (50 mg) in the Treatment of Locally Advanced/Metastatic Prostate Cancer
    Agnihotri, Laxmi
    Gupta, Money
    Mandial, Vishal
    Kayastha, Anil
    INTERNATIONAL JOURNAL OF SCIENTIFIC STUDY, 2016, 3 (12) : 18 - 22
  • [47] Bicalutamide (‘Casodex’) 150 mg in addition to standard care in patients with nonmetastatic prostate cancer: updated results from a randomised double-blind phase III study (median follow-up 5.1 y) in the early prostate cancer programme
    M Wirth
    C Tyrrell
    K Delaere
    M Sánchez-Chapado
    J Ramon
    D M A Wallace
    J Hetherington
    F Pina
    C Heyns
    T Borchers
    T Morris
    J Armstrong
    Prostate Cancer and Prostatic Diseases, 2005, 8 : 194 - 200
  • [48] Bicalutamide ('Casodex') 150 mg in addition to standard care in patients with nonmetastatic prostate cancer:: updated results from a randomised double-blind phase III study (median follow-up 5.1 y) in the early prostate cancer programme
    Wirth, M
    Tyrrell, C
    Delaere, K
    Sánchez-Chapado, M
    Ramon, J
    Wallace, DMA
    Hetherington, J
    Pina, F
    Heyns, C
    Borchers, T
    Morris, T
    Armstrong, J
    PROSTATE CANCER AND PROSTATIC DISEASES, 2005, 8 (02) : 194 - 200
  • [49] Can lifestyle changes affect the progression of prostate cancer? Results from the prostate cancer lifestyle trial
    Weidner, G
    PSYCHOLOGY & HEALTH, 2005, 20 : 288 - 289
  • [50] Salvage therapy with bicalutamide 80mg in patients with PSA failure under medical or surgical castration for prostate cancer
    Fujii, Y.
    Kawakami, S.
    Kobayashi, T.
    Masuda, H.
    Koga, F.
    Saito, K.
    Sakai, Y.
    Kageyama, Y.
    Kihara, K.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
12345